07-SEP-2025 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 N 0 Screening 1420 1448 130 0 0 0 0 08/13/2019 26 5
            1448 130 0 0 0 0      
 
    2 Y 1 Lenalidomide   674 67 6 0 0 0 08/13/2019    
        2 Lenalidomide + Daratumumab   664 63 7 2 0 0      
            1338 130 13 2 0 0      
 
    3 Y 3 Stop vs Continue Treatment   275 75 32 3 0 0 08/13/2019    
            275 75 32 3 0 0      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 92 9 7 3 1 1 0 01/05/2022 109 28
        2 I+R+Venetoclax   1 0 0 0 0 0      
        3 V+R   8 5 3 2 1 0      
            18 12 6 3 2 0      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 31 20 8 2 1 0 10/12/2023 258 82
        2 DRD-R   34 20 11 7 3 0      
        3 DRD-DR   31 19 11 6 3 0      
            96 59 30 15 7 0      
 
  S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Y 0 Induction 338 20 17 9 6 1 0 07/01/2024 149 44
            20 17 9 6 1 0      
 
    2 Y 1 Dara-VCD   4 4 3 1 0 0 07/01/2024    
        2 Melphalan + ASCT   4 4 2 1 0 0      
            8 8 5 2 0 0      
 
    3 Y 3 Dara   2 2 1 1 0 0 07/01/2024    
            2 2 1 1 0 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   59 12 8 5 0 0 05/27/2021 229 80
            59 12 8 5 0 0      
 
    1 E Total Registrations   44 9 7 4 1 1 05/27/2021    
            44 9 7 4 1 1      
 
    2 E Total Registrations   31 8 2 2 0 0 05/27/2021    
            31 8 2 2 0 0      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   80 9 5 4 2 0 01/08/2020 252 101
            80 9 5 4 2 0      
 
    1 E Total Registrations   39 7 2 2 1 0 01/08/2020    
            39 7 2 2 1 0      
 

07-SEP-2025 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2005 WM, Prev. Untreated, I/R +/- Venetoclax 2 Crossover 24-Jun-21 109 28